目的 了解2017年天津醫(yī)科大學(xué)代謝病醫(yī)院門(mén)診降糖藥物的使用情況，為臨床合理用藥提供依據(jù)。方法 采用WHO推薦的限定日劑量（DDD）法對(duì)2017年天津醫(yī)科大學(xué)代謝病醫(yī)院治療糖尿病藥物的種類(lèi)、規(guī)格、銷(xiāo)量、銷(xiāo)售金額、用藥頻度（DDDs）、日均費(fèi)用（DDC））和排序比（B/A）等進(jìn)行統(tǒng)計(jì)分析。結(jié)果 胰島素注射液的銷(xiāo)售金額及構(gòu)成比在各類(lèi)降糖藥物中一直位居第1位，口服降糖藥中α-葡萄糖苷酶抑制劑的銷(xiāo)售金額遠(yuǎn)超其他5類(lèi)口服降糖藥，占比27.50%。雙胍類(lèi)藥物的年銷(xiāo)售數(shù)量居首位，其中鹽酸二甲雙胍片的銷(xiāo)量穩(wěn)居第1位，門(mén)冬胰島素30注射液的銷(xiāo)量在眾多胰島素中排名第1位。DDDs排序前5名的藥品為阿卡波糖片、格列美脲片、瑞格列奈片、門(mén)冬胰島素30、鹽酸二甲雙胍片。胰島素注射液類(lèi)降糖藥的DDC普遍高于其他口服降糖藥。雙胍類(lèi)的B/A均高于1.00，α-葡萄糖苷酶抑制劑的B/A均低于1.00。結(jié)論 臨床應(yīng)選擇適合的降糖藥物來(lái)控制糖尿病患者的血糖，提高患者的依從性，降低患者的經(jīng)濟(jì)負(fù)擔(dān)，促進(jìn)臨床合理用藥。

Objective To investigate the use of anti-diabetic drugs in Metabolic Disease Hospital of Tianjin Medical University in 2017, and to provide reference for reasonable application of anti-diabetic drugs. Methods The applied category, specifications, sales volume, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of anti-diabetic drugs in Metabolic Disease Hospital of Tianjin Medical University in 2017 were analyzed statistically according to the WHO-recommended DDD (defined daily dose) method. Results Consumption sum and constituent ratio of Insulin Injection in various anti-diabetic drugs had always been the first. Consumption sum of α-glucosidase inhibitors in oral anti-diabetic drugs was far more than the other 5 types of oral hypoglycemic drugs, accounting for 27.50%. Annual sales volume of biguanides ranked the first, in which sales of Metformin Hydrochloride Tablets was at the first place. Sales of Insulin Aspart 30 Injection in all insulins ranked the first. Anti-diabetic drugs with top five DDDs were Acarbose Tablets, Glimepiride Tablets, Repaglinide Tablets, Insulin Aspart 30 Injection, and Metformin Hydrochloride Tablets. DDC of Insulin Injection was higher than that of other oral hypoglycemic drugs. B/A of biguanides was higher than 1.00, while B/A of α-glucosidase inhibitors was lower than 1.00. Conclusion The clinic should select a suitable anti-diabetic drug to control the blood glucose of the diabetic patients, improve the patient's compliance, reduce the economic burden of the patients, and promote rational drug use in the clinic.